Ziel Biosciences

Ziel Biosciences is a biotechnology company focused on developing innovative oncology therapies and diagnostics by targeting the sialic acid-Siglec axis, a key pathway in cancer immune evasion. The company's research centers on the role of hypersialylation in the tumor microenvironment, which suppresses immune responses by engaging inhibitory Siglec receptors on myeloid and lymphoid cells. Ziel is advancing a pipeline of monoclonal antibodies designed to block these interactions and restore anti-tumor immunity. Additionally, the company develops molecular diagnostic tools to identify patients most likely to benefit from its targeted therapies, particularly in gynecological and gastrointestinal cancers.